All In Biotech

Drug Trial Radar · NCT02343458

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo

Last checked: Nov 19, 2026Latest source record: Feb 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,756 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,756

Actual

Start

Mar 30, 2015

Primary completion

Aug 31, 2017

Study completion Aug 31, 2017

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • GFF MDI (PT003)Drug

    Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

  • FF MDI (PT005)Drug

    Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

  • GP MDI (PT001)Drug

    Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

  • Placebo MDIDrug

    Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)Time frame: at week 24
  2. Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan ApproachTime frame: over weeks 12-24
  3. Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.Time frame: over 24 weeks

Locations

166 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Andalusia, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Foley, Alabama

  • Research Site

    Jasper, Alabama

  • Research Site

    Anaheim, California

  • Research Site

    Boulder, Colorado

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Panama City, Florida

  • Research Site

    Pensacola, Florida

  • Research Site

    Tamarac, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Blue Ridge, Georgia

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Edina, Minnesota

  • Research Site

    Fridley, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Woodbury, Minnesota

  • Research Site

    Saint Charles, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Gastonia, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Dublin, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Medford, Oregon

  • Research Site

    Easley, South Carolina

  • Research Site

    Gaffney, South Carolina

  • Research Site

    Greenville, South Carolina

  • Research Site

    Rock Hill, South Carolina

  • Research Site

    Seneca, South Carolina

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.